This could be a key move for future growth.
Biogen Inc. (NASDAQ:BIIB) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, it was reported that ...
Pharmaceutical Technology on MSN
Biogen to acquire Raythera for up to $1bn
The proposed acquisition will add anti-inflammatory candidates to Biogen, including RayThera’s lead asset.
Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
June 17 (Reuters) - Biogen has struck a deal to acquire private biotechnology company RayThera for up to $1 billion, the companies said on Wednesday, as the U.S.-listed drugmaker seeks to expand its ...
Biogen reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance as cost-cutting efforts showed progress and sales of its breakthrough Alzheimer's drug, ...
Biogen Inc. (Nasdaq: BIIB) and RayThera Inc., a private biotechnology company focused on discovering and developing small molecule therapies in immunology, today announced the companies have entered ...
View Biogen Inc. BIIB stock quote prices, financial information, real-time forecasts, and company news from CNN.
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Biogen has agreed to pay $18.9 million to resolve a lawsuit alleging that it misled investors about the commercial readiness of the pharmaceutical company's Alzheimer's disease drug Aduhelm.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results